Pituitary TRH receptor (U.S. Patent Number 5,288,621)
Disclosed for the first time is the isolation, sequence, and expression cloning of a cDNA encoding for pituitary thyrotropin-releasing hormone receptor, as well as the amino acid sequence for the receptor per se. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Personalized Body Weight Management System Using Monitoring Devices and Mathematical Models of Metabolism
Attempts to manage body weight are often unsuccessful or only temporary. This is, in part, due to antiquated dieting methods that attempt to address calorie consumption while ignoring metabolic and physical changes. It is becoming clear that personalized methods to manage body weight must be developed.Scientists at the NIH have developed new methods for prescribing and monitoring personalized weight management interventions. The system uses validated mathematical models of human metabolism to set weight management goals and predict individual body weight outcomes in the context of changing metabolic needs and calorie consu...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Novel conjugate vaccine process, cholera vaccine (U.S. Patent Number 61/507,054)
A new conjugate vaccine for cholera has been developed. The invention includes a new method to conjugate the O-specific polysaccharide-core part of the bacterial lipopolysaccharide and protein subcomponents. Conventional technology has entailed chemical treatment of both components to introduce linkers, which made them amenable for covalent linking. The new method simplifies production by utilizing squaric acid chemistry for conjugating the free amine-containing species (e.g. polysaccharides) directly to amine-containing species (e.g. proteins) without prior modification of either component. While demonstrated in this new ...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Nicotinic acetylcholine receptor agonists (U.S. Patent Application Number WO 2011116282 A3)
The invention provides novel nicotinic acetylcholine receptor agonists, for example, phaiitasmidine and derivatives thereof, for example a compound of formula (I). Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acet lcholine rece tor a onists. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Mutant Mouse: Kmt2d (lysine (K)-specific methyltransferase 2D) (MII4 LoxP Mouse)
Mll4-flox. Conditional knockout mice for the histone methyltransferase Mll4 (Kmt2d) will help understand its role as a tumor suppressor.Mono- and di-methylations on histone H3 lysine 4 (H3K4me1 and H3K4me2) are epigenetic marks for transcriptional enhancers, which control cell type-specific gene expression. Mll4, also known as Kmt2d (lysine (K)-specific methyltransferase 2D), is a major mammalian histone H3K4 mono- and di-methyltransferase enriched on enhancers (http://www.ncbi.nlm.nih.gov/pubmed/24368734). Mll4 knockout mice are early embryonic lethal, so we have generated Mll4 conditional knockout mice (Mll4-flox) in whi...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Mutant Mouse: Kdm6a (lysine (K)-specific demethylase 6A) (UTX Knockin Mouse)
UTX-KI. Enzyme-dead knockin (KI) mice for the histone demethylase UTX (Kdm6a) will help understand its role in tumor suppression and stem cell-mediated tissue regeneration.Di- and tri-methylations on histone H3 lysine 27 (H3K27me2 and H3K27me3) are epigenetic marks for gene repression. UTX (ubiquitously transcribed X chromosome protein), also known as Kdm6a (lysine (K)-specific demethylase 6a), is a histone demethylase that specifically removes H3K27me2 and H3K27me3. To investigate the physiological role of UTX enzymatic activity, we have generated UTX enzyme-dead knockin mice (UTX-KI) which possess the H1146A and E1148A p...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
MUP-tTA Mouse
Tetracycline-responsive transcriptional activator driven by the liver-specific mouse major urinary protein promoter (MUP-tTA).TheE. Coli tetracycline operon regulatory system was used to generate a liver-specific transcription activation system that was inhibited by tetracycline. The transcription activator was a fused protein consisting of a tetracycline repressor gene (tetR) that was only active in the presence of tetracycline and a herpes simplex virus protein (VP-16) transcription activating domain (Tet-Off). Transcription was induced only in the absence of tetracycline (Tet-Off). A liver-specific promoter such as the ...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Mini Mu containing plasmid and a method for rapid DNA sequencing (U.S. Patent Number 4,716,105)
The present invention discloses a rapid method of sequencing a relatively large segment of deoxyribonucleic acid. The method in part comprises high frequency insertion of a suitable transposon into a segment of DNA of interest. Preferable use of Mu transposons is described. A plasmid having mini-Mu transposons has been prepared and disclosed. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Methods of preventing viral replication (U.S. Patent Number 5,610,050)
The invention relates to methods and compositions for inhibition of viral replication. In particular, termination of replication of hepatitis B virus is achieved by introducing into a target cell an antisense oligonucleotide having a sequence substantially complementary to an mRNA which is in turn complementary to a portion of the minus strand of a hepatitis viral genome, which portion encoding solely part or all of the terminal protein region of the viral polymerase. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor (U.S. Patent Number 6,403,305)
The present invention is directed to a strategy to discover small peptides that will activate any G protein coupled receptor (GPCR) or inactivate any constitutively active GPCR. The strategy uses combinatorial peptide libraries to screen millions of random peptides for agonist/negative antagonist activity. The method of the subject invention comprises expressing a peptide of a peptide library tethered to a G protein coupled receptor of interest in a cell, and monitoring the cell to determine whether the peptide is an agonist or negative antagonist of the GPCR of interest. The peptide is tethered to the GPCR by replacing th...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Methods of identifying negative antagonists for G protein coupled receptors (U.S. Patent Number 6,087,115)
The present invention is directed to a constitutively active G protein coupled receptor of human herpesvirus 8, as well as a method of identifying negative antagonists of a constitutively active G protein coupled receptor. The method comprises co-expressing in a host cell a constitutively active G protein coupled receptor and a reporter protein, wherein expression of the reporter protein is controlled by a promoter responsive to a signalling pathway activated by the constitutively active G protein coupled receptor; exposing the host cell to a test substance; and determining a level of reporter protein activity, wherein the...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Methods for reducing Intraocular Pressure using A3 Adenosine Receptor Antagonists (U.S. Patent Number 6,528,516)
This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Methods for preparing Bacillus anthracis protective antigen for use in vaccines (U.S. Patent Number 7,763,451)
The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Methods for delivering biologically active molecules into cells (U.S. Patent Number 6,974,698)
Methods for delivering a biologically active molecule into a cell by linking a molecule to the cell surface, wherein the molecule can act as a surface receptor, then complexing the biologically active molecule with a ligand for the surface receptor, and finally contacting the biologically active molecule-ligand complex with the cell surface are disclosed. Delivery of any biologically active molecule, e.g. proteins, enzymes, nucleic acids, hormones, nucleic acids, and oligonucleotides, is contemplated. The use of biotin or biotinylated antibodies as the surface receptor is disclosed. The use of PEI and PEI-avidin conjugates...
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
Methods and pharmaceutical compositions for inhibiting tumour cell growth (U.S. Patent Application Number WO 1998025598 A2)
Methods for inhibiting proliferation of a PPAR η-responsive hyperproliferative cell using PPARη agonists are described. Pharmaceutical compositions as well as methods for diagnosing and treating a PPARη-responsive hyperproliferative cell are also described. (Source: NIDDK Research Resources)
Source: NIDDK Research Resources - February 16, 2017 Category: Endocrinology Source Type: research
